KDM6A and multiple sclerosis: Global transcriptome analysis in CD4+ T lymphocytes isolated from these knockout mice revealed that specific pathways associated with Th1 and Th2 cell activation were upregulated [262], and it was therefore suggested that modulating the activity Kdm6a in T lymphocytes could be a potential targeted therapeutic approach to treat multiple sclerosis and other autoimmune diseases in which these cells play a role.